NAPLES, Fla., June 30, 2025 (GLOBE NEWSWIRE) -- via IBN -- HealthLynked Corp. (OTCQB: HLYK), a leader in connected healthcare technology, is pleased to announce the appointment of Andrew Mavliev as its new Chief Technology and Product Officer. With over 15 years of experience in technology strategy, product development, and operational leadership, Mavliev brings a transformative vision to HealthLynked's executive team. HealthLynked is revolutionizing healthcare delivery through its integrated digital ecosys ...

Core Insights - Nebius has launched its inaugural AI Discovery Awards to support innovative companies in healthcare and life sciences, providing over $850,000 in GPU cloud and inferencing credits [1][6] Group 1: Award Winners and Their Innovations - Ataraxis AI won for its cancer treatment prediction platform, achieving 30% higher accuracy than standard genomic tests in clinical validation across 7,500 patients [2] - Aikium focuses on targeting "undruggable" proteins, which comprise half of the human proteome, using its Yotta-ML² platform and has secured partnerships with three top cancer hospitals [3] - Transcripta Bio has developed a high-resolution transcriptomic atlas with over a billion gene responses, recently partnering with Microsoft Research to identify new disease-gene associations [4] - MetaSight Diagnostics is pioneering advanced blood testing for population-scale disease diagnostics, creating the world's largest blood molecular database from over 500,000 participants [5] Group 2: Award Structure and Benefits - Each category winner receives $100,000 in GPU credits, with second and third places receiving $50,000 and $30,000 respectively, along with mentorship and networking support [7] - Seven "honorable mentions" in each category receive $5,000 in GPU cloud credits, and all participants are granted inferencing credits for Nebius AI Studio [7] Group 3: Industry Impact and Future Directions - Nebius aims to connect promising companies leveraging AI in healthcare with the necessary computational infrastructure and expertise to scale their innovations [6] - The awards highlight significant advancements in applying AI to healthcare challenges, such as predicting cancer treatment outcomes and targeting previously undruggable proteins [8]

Core Viewpoint - Premier Health of America Inc. has initiated a formal strategic review process to explore various strategic alternatives aimed at enhancing shareholder value [1][2]. Group 1: Strategic Review Process - The Board of Directors has engaged Leede Financial Inc. as a financial advisor to assist in the strategic review [2]. - No definitive timetable has been set for the completion of the review, and no decisions regarding potential strategic alternatives have been made at this time [2]. - The company does not plan to disclose further developments unless deemed appropriate or necessary [2]. Group 2: Management Focus and Incentives - While the review is ongoing, the management team is committed to delivering organic growth and maintaining service continuity across Canada [3]. - A targeted retention and incentive framework for key executives has been approved to ensure operational continuity and align management objectives with shareholder value creation during the review process [3]. Group 3: Company Overview - Premier Health is a leading Canadian health tech company that offers a comprehensive range of outsourced healthcare services to governments, corporations, and individuals [4]. - The company utilizes its proprietary LiPHe platform to drive digital transformation in the healthcare services sector, aiming to provide faster, cheaper, and more accessible care [4].

Core Viewpoint - Premier Health of America Inc. reported a significant decline in revenues and increased net loss for the second quarter ended March 31, 2025, primarily due to the impact of Quebec's Bill 10 and operational challenges in British Columbia [1][4][10]. Financial Performance - Revenues for Q2 2025 were CAD 27.1 million, down from CAD 46.3 million in Q2 2024, representing a decrease of approximately 41.4% [3]. - Gross margin for Q2 2025 was CAD 4.5 million, compared to CAD 8.5 million in Q2 2024, with gross margin as a percentage of revenues decreasing from 18.4% to 16.7% [3]. - Adjusted EBITDA for Q2 2025 was CAD 0.5 million, down from CAD 2.6 million in the same period of 2024 [10]. - The net loss for Q2 2025 was CAD 3.1 million, compared to a loss of CAD 1.5 million in Q2 2024 [10]. Operational Challenges - The implementation of Quebec's Bill 10 has significantly impacted the Per Diem segment, which now accounts for about 4% of revenues and 5% of gross margins [4]. - The travel nurse and northern communities' services are performing well, except for a volume reduction in British Columbia due to health authorities' service acquisition centralization efforts [5]. - The company is undergoing a reorganization of its Quebec operations, including workforce reductions and termination of targeted office leases, with cost savings expected to continue in the coming quarters [6]. Strategic Focus - The company is shifting its focus from the Per Diem segment to Travel Nurses and is exploring opportunities in the Home Care sector [7]. - The CFO, Guy Daoust, has taken on the role of interim CEO, emphasizing the need for further steps to adapt to ongoing operational challenges [5][7].

PitchBook Data, Inc. Nizar Tarhuni Executive Vice President of Research and Market Intelligence Paul Condra Global Head of Private Markets Research James Ulan Director of Emerging Technology Research Institutional Research Group Analysis Aaron DeGagne, CFA Senior Research Analyst, Healthcare aaron.degagne@pitchbook.com pbinstitutionalresearch@pitchbook.com Publishing Designed by Josie Doan Published on May 8, 2025 Contents | Introduction | 1 | | --- | --- | | Key takeaways | 2 | | Momentum for European heal ...

MONTRÉAL, May 01, 2025 (GLOBE NEWSWIRE) -- Premier Health of America Inc. (TSXV: PHA) (the “Corporation” or “Premier Health”), a leading Canadian Healthtech company, announces that all matters submitted to shareholders for approval were approved at its annual general meeting of shareholders held on April 30, 2025. All matters submitted to shareholders for approval as set out in detail in the Corporation’s management Information Circular dated April 4, 2025, were approved at its annual general meeting of sha ...

MONTRÉAL, March 27, 2025 (GLOBE NEWSWIRE) -- Premier Health of America Inc. (TSXV: PHA) (the “Corporation”), a leading Canadian Healthtech company, announces that Martin Legault has resigned from his role as President and Chief Executive Officer of the Corporation, as well as from his position on the Board of Directors, effective as of March 27, 2025. The Corporation thanks Mr. Legault for his 22 years of service and leadership. Guy Daoust, the Chief Financial Officer of the Corporation, has been appointed ...